Baidu
map

荐读|药品管理法修改,拟重罚生产销售假药劣药行为!云南白药回应:牙膏无违法添加成分!

2018-10-24 毕雪立 整理 医师报

行业新闻 1、云南白药回应:我们没有欺骗消费者 10月23日9时许,身在风暴之中的云南白药集团在官网发布声明称,云南白药牙膏所使用的所有成分均符合国家《牙膏用原料规范》,无违法添加成分,更未使用禁用成分。氨甲环酸是广泛运用于功效牙膏中的一种常用成分,目前国内外多种功效牙膏都使用了此成分。同时,云南食药监局表示氨甲环酸不在牙膏生产的禁用成分名单内,所以目前仍可以使用。为了探究答案,《医师


行业新闻

1、云南白药回应:我们没有欺骗消费者

10月23日9时许,身在风暴之中的云南白药集团在官网发布声明称,云南白药牙膏所使用的所有成分均符合国家《牙膏用原料规范》,无违法添加成分,更未使用禁用成分。氨甲环酸是广泛运用于功效牙膏中的一种常用成分,目前国内外多种功效牙膏都使用了此成分。同时,云南食药监局表示氨甲环酸不在牙膏生产的禁用成分名单内,所以目前仍可以使用。为了探究答案,《医师报》记者在著名牙膏品牌狮王牙膏的生产企业日本狮王株式会社的官网查证发现,牙膏中添加氨甲氨酸成分的主要作用是抗炎,用于预防牙龈炎和牙周炎,防止出血。这似乎能从侧面回答部分功效牙膏的止血功效到底谁在发挥作用。(来源:医师报)

2、《基本医疗卫生与健康促进法(草案)》进入二审

10月22日,第十三届全国人大常委会第六次会议在北京召开。会上,《基本医疗卫生与健康促进法(草案)》(二次审议稿)提交审议。与一审稿相比,二审稿在强基层、人才培养、“三医联动”、药品管理等方面进行了修改完善。(来源:健康报)

3、药品管理法修改,拟重罚生产销售假药劣药行为

10月22日下午,十三届全国人大常委会第六次会议在京举行,本次会议对药品办理法批改草案进行了一审。国家药品监督办理局局长焦红作了关于药品办理法批改草案的阐明。修正草案新增规定,县级以上地方政府存在三种特定行为的,对直接负责的主管人员和其他直接责任人员给予记过或者记大过处分,情节严重的,给予降级、撤职或者开除处分。此外,本次修正草案还新增规定,药品监督管理部门存在“对发现的药品安全违法行为未及时查处”等三种行为的,对直接负责的主管人员和其他直接责任人员给予记过或者记大过处分,情节较重的,给予降级或者撤职处分;情节严重的,给予开除处分。(来源:北青网-北京青年报)

4、国家药监局@你,这19批次药品不合规

近日,国家药品监督管理局发布关于19批次药品不符合规定的通告,经中国食品药品检定研究院等6家药品检验机构检验,标示为苏州弘森药业股份有限公司等17家企业生产的19批次药品不符合规定。详情请登录国家药品监督管理局官微查看(来源:国家药品监督管理局)

学术新闻

1、卡马西平和丙戊酸增双相障碍患者卒中风险

心脑血管疾病是双相障碍患者过早死亡的主要原因之一。近期中国台湾一项研究显示,双相障碍患者的卒中风险与使用心境稳定剂有关,且和心境稳定剂使用剂量呈正性相关。在临床常用的四种心境稳定剂中,卡马西平的卒中风险最高,丙戊酸盐次之,锂盐和拉莫三嗪不会增加卒中风险。(来源:医师报)

2、女性泌乳素可降低2型糖尿病风险?言之过早!

美国一项研究发现,与母乳喂养相关的一种激素——泌乳素在降低2型糖尿病上扮演重要角色,与正常范围内泌乳素水平最低的女性相比,泌乳素水平最高的女性(仍在正常范围)患2型糖尿病的风险降低27%。研究者表示,根据现有的研究结果,得出改变泌乳素的浓度能够有效预防糖尿病的结论或许还为时尚早。此外,正常情况下,高水平的泌乳素还与乳腺癌风险增加有关,还会促进体重增加及胰岛素耐受性增加等。仍需进一步研究机制确定该结果的临床价值。(来源:医师报)

3、JCO:改善直肠癌预后从健康的饮食开始

美国癌症协会(American cancer Society)的一项新研究显示,遵循健康饮食的直肠癌患者死于结直肠癌及其他原因的风险较低,甚至是那些在确诊后改善了饮食的患者也是如此。(来源:生物探索)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]
    2018-10-26 gongliu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1687320, encodeId=6554168e32002, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Feb 25 11:49:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776891, encodeId=4b4f1e76891f9, content=<a href='/topic/show?id=3baf9449415' target=_blank style='color:#2F92EE;'>#违法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94494, encryptionId=3baf9449415, topicName=违法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a65839047655, createdName=dinorsor537, createdTime=Thu Mar 21 14:49:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659377, encodeId=7ca316593e78e, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Sun Feb 10 16:49:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052456, encodeId=c1d42052456a6, content=<a href='/topic/show?id=aaba2e592d7' target=_blank style='color:#2F92EE;'>#假药劣药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27592, encryptionId=aaba2e592d7, topicName=假药劣药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Jun 02 04:49:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319617, encodeId=89d8131961e2c, content=<a href='/topic/show?id=d2ec8e469e5' target=_blank style='color:#2F92EE;'>#药品管理法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87469, encryptionId=d2ec8e469e5, topicName=药品管理法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456529, encodeId=ba481456529e4, content=<a href='/topic/show?id=87c02e591df' target=_blank style='color:#2F92EE;'>#假药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27591, encryptionId=87c02e591df, topicName=假药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a55763372, createdName=gongliu, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517782, encodeId=4e61151e7828e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Oct 26 00:49:00 CST 2018, time=2018-10-26, status=1, ipAttribution=)]

相关资讯

专家谈《药品管理法》修订:从“重发证”转向“重监管”

10月23日,国家食药监总局公开征求《〈药品管理法〉修正案(草案征求意见稿)》(下称“草案”)意见,这是近日《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》印发后的系列改革动作之一。10月24日,中国医药创新促进会执行会长宋瑞霖在接受澎湃新闻(www.thepaper.cn)采访时表示,“特别是国际化方面的改革,迈出了很大的一步。”草案中最能体现向国际化靠拢的改变是全面施行药品上市许可持有人

定了!GMP、GSP认证取消!批文转让大放开

《药品管理法》要变,取消GMP、GSP认证,写进法律!药品文号可合法转让!

药品管理法拟围绕疫苗事件暴露问题进行修改:从四方面重罚

药品管理法草案围绕问题疫苗案件暴露的突出问题、实施药品上市许可持有人制度和推进审批制度改革等进行了修改,及时回应社会关切。

《药品管理法》大修改 这些内容全变了!

近日(9月6日),参与药品监管法规修订的权威人士,在公开场合透露:《药品管理法(修正案)》(以下简称《修正案》)有关内容已提交司法部,力争10月底提交全国人大常委会审议,《药品管理法》全面修订草案力争2019年底提交司法部。

疫苗立法**!人大常委会修正《药品管理法》

10月22日,全国人大常委会对《药品管理法修正草案》进行了初次审议,相比于原有《药品管理法》,本次草案增添了多条关于药品的新规,其中疫苗立法是重点布局方向,让我们一起来看一看。

药品管理法修正草案提交审议 增加疫苗条款

“重典治乱” 保民健康——药品管理法修正草案四大亮点及时回应社会关切

Baidu
map
Baidu
map
Baidu
map